Skip to main navigation
Skip to search
Skip to main content
Mayo Clinic Home
Home
Profiles
Departments/Divisions
Grants
Research output
Prizes
Search by expertise, name or affiliation
Targeting myeloproliferative neoplasms with JAK inhibitors
Animesh Pardanani
,
Ayalew Tefferi
Hematology
Research output
:
Contribution to journal
›
Article
›
peer-review
33
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Targeting myeloproliferative neoplasms with JAK inhibitors'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine & Life Sciences
Janus Kinase Inhibitors
100%
N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
46%
Primary Myelofibrosis
44%
Essential Thrombocythemia
31%
Polycythemia Vera
30%
Fedratinib
23%
Neoplasms
23%
INCB018424
18%
Splenomegaly
13%
Therapeutics
11%
Anemia
10%
Adenosine Triphosphate
9%
Mutation
6%